ContactDictionary

Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  abemaciclib
Find trials that include:  Any drugs shown
Results 1-17 of 17 for your search:
Start Over
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15450, NCI-2015-00514, 2014-004010-28, I3Y-MC-JPBO, NCT02308020
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15804, NCI-2016-00389, 2015-003400-24, I3Y-MC-JPBZ, NCT02675231
Abemaciclib in Treating Patients with Recurrent, Locally Advanced, or Metastatic Dedifferentiated Liposarcoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-376, NCI-2016-01223, NCT02846987
Abemaciclib in Treating Patients with Recurrent Glioblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-383, NCI-2017-00385, NCT02981940
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16339, NCI-2017-00442, 2016-000288-18, I3Y-MC-JPCG, NCT02747004
Abemaciclib, DNA-PK/TOR Kinase Inhibitor CC-115, or Neratinib in Treating Patients with Brain Tumors after Biomarker Screening
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-443, NCI-2017-00433, NCT02977780
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16342, NCI-2017-00608, 2016-002218-36, I3Y-MC-JPCJ, NCT02981342
Abemaciclib in Treating Patients with Rb Positive Triple-Negative Breast Cancer That is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 17-024, NCI-2017-01192, NCT03130439
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15252, NCI-2014-01032, I3Y-MC-JPBH, NCT02057133
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15266, NCI-2014-00892, 2013-004648-41, I3Y-MC-JPBJ, KEYNOTE-238, NCT02079636
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 to 21
Trial IDs: AFLACST1501, NCI-2015-02256, IRB00083793, NCT02644460
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis
Age: 18 and over
Trial IDs: 15537, NCI-2016-00912, I3Y-MC-JPCB, NCT02688088
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16209, NCI-2016-01101, 2015-004421-14, I6F-MC-JJCD, NCT02784795
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16177, NCI-2016-01192, 2015-005156-94, I3Y-MC-JPCE, KEYNOTE 287, NCT02779751
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16165, NCI-2017-00003, 2015-004381-28, I4T-MC-JVDK, NCT02745769
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 120 and over
Trial IDs: 16419, NCI-2017-00039, 2016-001907-21, I8S-MC-JUAB, NCT02857270
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 1280.18, NCI-2017-01042, NCT03099174
Start Over